Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in thyroid cancer
- Trial result
Thyroid cancer
Selpercatinib (selective RET inhibitor) posts 53% ORR with 2-year durability in pediatric RET-altered tumors
Selpercatinib is an oral, CNS-active, highly selective RET tyrosine kinase inhibitor evaluated in the multicenter Phase I/II LIBRETTO-121 trial (NCT03899792) in children/adolescents/young adults age 0.5–21 with…
NCT03899792 - Trial result Spotlight
Thyroid cancer
Dabrafenib + trametinib (BRAF/MEK) cuts progression risk in BRAF V600E thyroid cancer
Dabrafenib, a BRAF inhibitor, plus the MEK inhibitor trametinib was tested in a global, randomized, double-blind Phase 3 trial (NCT04940052) in previously treated, radioactive iodine–refractory BRAF V600E–positive…
NCT04940052 - Trial result
Thyroid cancer
Atezolizumab (PD-L1) + MAPK-targeted therapy links ATC long survival to “inflamed + differentiated” tumors, not BRAF/RAS status
Atezolizumab is an anti–PD-L1 checkpoint inhibitor combined here with MAPK-pathway targeted therapy—BRAF V600E patients received vemurafenib (BRAF inhibitor) + cobimetinib (MEK inhibitor), while RAS/NF-mutant…
NCT03181100 - Trial result Spotlight
Thyroid cancer
Pralsetinib (selective RET inhibitor) drives 92% ORR in pretreated RET fusion+ thyroid cancer; 68% ORR in RET-altered MTC
Pralsetinib is an oral, potent, selective RET tyrosine kinase inhibitor evaluated in the Phase 1/2 ARROW study (NCT03037385) in advanced/metastatic RET-altered thyroid cancer and medullary thyroid cancer (MTC). At…
NCT03037385 - Trial result
Thyroid cancer
THYRO-RT Finds No Significant LRR Benefit From Adjuvant EBRT in High-Risk Thyroid Cancer
THYRO-RT (NCT03669432) randomized patients with high-risk resected non-medullary, non-anaplastic thyroid cancer to surgery plus RAI versus surgery plus RAI and adjuvant EBRT (60 Gy/30 fractions). The cohort was very…
NCT03669432 - New trial
Thyroid cancer
Phase 2 STAGE‑MTC evaluates thyroid lobectomy; no drug target (surgery de‑escalation).
This Jonsson Comprehensive Cancer Center–sponsored, single-arm surgical trial tests whether thyroid lobectomy plus ipsilateral (unilateral) central neck dissection can adequately treat resectable sporadic medullary…
NCT07612293 Exploratory - New trial
Thyroid cancer
Phase II Lenvatinib Trial: Multikinase Inhibitor for Radioactive Iodine Resistant Thyroid Cancer
In this open-label, randomized Phase II trial sponsored by Washington University School of Medicine, two dosing regimens of lenvatinib (a multikinase inhibitor) are compared to determine optimal dose delivery,…
NCT07092514 Exploratory - New trial
Thyroid cancer
Phase 1/2 trial of 177Lu-DOTA-EB-TATE, somatostatin receptor directed beta emitter
This open-label study tests a three-dose regimen of 177Lu-DOTA-EB-TATE to assess safety, dosimetry, and efficacy in adults with metastatic, radioactive iodine non-responsive Hurthle cell thyroid cancer. Sponsored by…
NCT06991738 Exploratory - Trial result
Thyroid cancer
Pembrolizumab + dabrafenib/trametinib drives 97% R0/R1 resections and 20-mo OS in BRAF V600E anaplastic thyroid cancer
Neoadjuvant BRAF inhibitor DTP, the combination of dabrafenib (150 mg BID) + trametinib (2 mg QD) for 3-6 weeks followed by pembrolizumab 200 mg Q3W—was tested in a multicenter phase 2 trial (NCT04675710) enrolling…
NCT04675710 - Trial result
Thyroid cancer
KL590586 RET-Targeted TKI Yields 63% ORR and 78% 2-Year PFS in Advanced Medullary Thyroid Cancer
KL590586 (A400/EP0031) is a next-generation, brain-penetrant selective RET inhibitor engineered to tackle resistance mutations. In the phase I dose-escalation/expansion KL400-I/II-01 study (NCT05265091) in China, 27…
NCT05265091 - Trial result
Thyroid cancer
Larotrectinib Delivers 79% ORR and 71% Six-Year OS in NTRK-Fusion Differentiated Thyroid Cancer
Larotrectinib, a highly selective CNS-penetrant TRK inhibitor, was pooled across three trials (n=31; NCT02576431, NCT02122913, NCT02637687). In advanced TRK-fusion thyroid carcinoma, adults received 100 mg BID. Among…
NCT02576431 - New trial
Thyroid cancer
Phase II Study of Lenvatinib & Pembrolizumab (PD-1) in Unresectable Anaplastic Thyroid Cancer
M.D. Anderson is evaluating the combination of lenvatinib, a multikinase inhibitor, with pembrolizumab, a PD-1 monoclonal antibody, in patients with stage IVB unresectable or stage IVC metastatic anaplastic thyroid…
NCT04171622 - New trial
Thyroid cancer
Neoadjuvant Treatment With Zanzalintinib for Advanced Thyroid Cancer
MD Anderson is conducting a trial to assess the safety and effectiveness of zanzalintinib (100 mg daily) followed by surgery in advanced thyroid cancers—both medullary (non-RET mutant) and non-medullary subtypes.
NCT06959511 - New trial
Thyroid cancer
Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer
This phase II trial is evaluating XL092, a tyrosine kinase inhibitor, as first-line therapy for advanced thyroid cancer that no longer responds to radioiodine treatment. Patients receive daily oral dosing with…
NCT06959641 - New trial
Thyroid cancer
Comparison of I-124 PET/CT to I-123 Imaging for Metastatic Thyroid Cancer
This single-arm prospective study compares the efficacy of I-124 PET/CT with traditional I-123/I-131 imaging in metastatic thyroid cancer patients, using an oral dose of I-124 followed by PET/CT scanning 20–28 hours…
NCT06961084 - Trial result
Thyroid cancer
ICAM-1 CAR-T Therapy AIC100 Yields Promising Responses in Aggressive Thyroid Cancers
In this Phase 1 dose-escalation study (NCT04420754), AIC100—a novel, ICAM-1 directed third-generation CAR T-cell therapy engineered with somatostatin receptor 2 for imaging—was evaluated in patients with…
NCT04420754
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.